UPDATE: Bank Of America On Biogene Also Continues To Think Zanu Has A High Probability Of Success 'to beat ibrutinib in Ph3 WM (Waldenstrom macroglobulinemia) trial, whose results will be reported by YE19'

Do you like seeing these details as to why an analyst recommended a stock? What could we do to make this product better? Let us know by emailing newsdesk@benzinga.com

Benzinga · 11/18/2019 17:49